Estrella Immunopharma, Inc. announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a... announced that the first patient has been successfully dosed in the dose-expansion phase of…
Estrella Immunopharma activated a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or... Estrella Immunopharma activated a fourth clinical site for its ongoing STARLIGHT-1 Phase I…
Estrella Immunopharma, Inc. announced the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a... announced the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II…
Estrella Immunopharma said Friday that the first patient has been dosed in the dose-expansion phase of its STARLIGHT-1 phase 1/2 clinical trial of EB103 to treat patients with relapsed/refractory... Biotechnology & Medical Research Estrella Immunopharma's Trial of EB103 to Treat Lymphoma Doses First…
Estrella Immunopharma, Inc. announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in... announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase…
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory... IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers…
US-based biotechnology company HealthBio has initiated a multi-centre clinical trial, HBT-002, to assess its lead compound Inflamexa in adult patients with post-treatment Lyme disease syndrome (PTLDS). Designated under IND185316, the double-blind, placebo-controlled study plans to enrol around 252 participants across at least…
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT designation and participation in the FDA CMC…
Oct 31, 2025, 04:00 ET The study has been carried out at two clinical centres: the Erasmus University Medical Centre, Rotterdam, in the Netherlands, and the Leonard Wolfson Experimental Neurology Centre Clinical Research Facility at the National Hospital for Neurology and Neurosurgery, University…
Summary of Critical Appraisal Even if pulmonary function test results have not changed significantly, patients may feel that "climbing stairs is difficult," "I am anxious about going outside," or "I cannot live like I used to." In the clinical management…
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
An article joins this feed when it matches these terms. Each one is also a search of its own.